دورية أكاديمية
First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof-of-concept study.
| العنوان: | First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof-of-concept study. |
|---|---|
| المؤلفون: | Bardol T; Laboratory of Rare Circulating Human Cells-University Medical Center of Montpellier, Montpellier, France.; CREEC/CANECEV, MIVEGEC (CREES), Université de Montpellier, CNRS, IRD, Montpellier, France., Eslami-S Z; Laboratory of Rare Circulating Human Cells-University Medical Center of Montpellier, Montpellier, France.; CREEC/CANECEV, MIVEGEC (CREES), Université de Montpellier, CNRS, IRD, Montpellier, France.; European Liquid Biopsy Society (ELBS), Hamburg, Germany., Masmoudi D; Laboratory of Rare Circulating Human Cells-University Medical Center of Montpellier, Montpellier, France.; CREEC/CANECEV, MIVEGEC (CREES), Université de Montpellier, CNRS, IRD, Montpellier, France., Alexandre M; Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, Montpellier, France.; Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Montpellier University, Montpellier, France., Duboys de Labarre M; Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, Montpellier, France.; Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Montpellier University, Montpellier, France., Bobrie A; Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, Montpellier, France.; Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Montpellier University, Montpellier, France., D'Hondt V; Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, Montpellier, France.; Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Montpellier University, Montpellier, France., Guiu S; Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, Montpellier, France.; Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Montpellier University, Montpellier, France., Kurma K; Laboratory of Rare Circulating Human Cells-University Medical Center of Montpellier, Montpellier, France.; CREEC/CANECEV, MIVEGEC (CREES), Université de Montpellier, CNRS, IRD, Montpellier, France.; European Liquid Biopsy Society (ELBS), Hamburg, Germany., Cayrefourcq L; Laboratory of Rare Circulating Human Cells-University Medical Center of Montpellier, Montpellier, France.; CREEC/CANECEV, MIVEGEC (CREES), Université de Montpellier, CNRS, IRD, Montpellier, France.; European Liquid Biopsy Society (ELBS), Hamburg, Germany., Jacot W; Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier University, Montpellier, France.; Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Montpellier University, Montpellier, France., Alix-Panabières C; Laboratory of Rare Circulating Human Cells-University Medical Center of Montpellier, Montpellier, France.; CREEC/CANECEV, MIVEGEC (CREES), Université de Montpellier, CNRS, IRD, Montpellier, France.; European Liquid Biopsy Society (ELBS), Hamburg, Germany. |
| المصدر: | Cancer medicine [Cancer Med] 2024 Jan; Vol. 13 (1), pp. e6843. Date of Electronic Publication: 2023 Dec 22. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Malden, MA] : John Wiley & Sons Ltd., c2012- |
| مواضيع طبية MeSH: | Neoplastic Cells, Circulating*/metabolism , Neoplastic Cells, Circulating*/pathology , Axl Receptor Tyrosine Kinase* , Receptor Protein-Tyrosine Kinases*/metabolism , Breast Neoplasms*/pathology , Breast Neoplasms*/blood , Breast Neoplasms*/metabolism , Breast Neoplasms*/genetics , Proto-Oncogene Proteins*/metabolism, Humans ; Female ; Middle Aged ; Cell Line, Tumor ; Aged ; Biomarkers, Tumor/metabolism ; Proof of Concept Study ; Neoplasm Metastasis ; Prospective Studies ; Adult |
| مستخلص: | Background: For several years, the AXL tyrosine kinase receptor, a member of the Tyro3-Axl-Mer (TAM) family, has been considered a new strategic target in oncology. AXL overexpression is common in solid tumors and is associated with poor prognosis. In this context, the detection of a subset of circulating tumor cells (CTCs) that express AXL (AXL + CTCs) could be clinically relevant. Methods: Immunostaining was performed to assess AXL expression in human breast cancer cell lines. The optimal conditions were established using flow cytometry. Spiking experiments were carried out to optimize the parameters of the CellSearch ® system detection test. CTC enumeration and AXL expression were evaluated in patients with metastatic breast cancer (mBC) before treatment initiation. Results: An innovative AXL + CTC detection assay to be used with the CellSearch ® system was developed. In a prospective longitudinal clinical trial, blood samples from 60 patients with untreated mBC were analyzed to detect AXL + CTCs with this new assay. CTCs were detected in 35/60 patients (58.3%) and AXL + CTCs were identified in 7 of these 35 patients (11.7% of all patients). Conclusion: This newly established AXL + CTC assay is a promising tool that can be used for liquid biopsy in future clinical trials to stratify and monitor patients with cancer receiving anti-AXL therapies. (© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.) |
| References: | Ferlay J, Ervik M, Lam F, et al. Observatoire Mondial du Cancer:«Cancer Today». Lyon: Centre international de recherche sur le cancer; 2020:P1. Pantel K, Alix‐Panabieres C. Liquid biopsy and minimal residual disease–latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16(7):409‐424. Pantel K, Alix‐Panabières C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med. 2010;16(9):398‐406. Alix‐Panabières C, Pantel K. Liquid biopsy: from discovery to clinical application. Cancer Discov. 2021;11(4):858‐873. Chambers AF, Naumov GN, Vantyghem SA, Tuck AB. Molecular biology of breast cancer metastasis. Clinical implications of experimental studies on metastatic inefficiency. Breast Cancer Res. 2000;2(6):400‐407. Kurma K, Alix‐Panabières C. Mechanobiology and survival strategies of circulating tumor cells: a process towards the invasive and metastatic phenotype. Front Cell Dev Biol. 2023;11:1188499. Cortes‐Hernandez LE, Eslami SZ, Alix‐Panabieres C. Circulating tumor cell as the functional aspect of liquid biopsy to understand the metastatic cascade in solid cancer. Mol Aspects Med. 2020;72:100816. Jiang X, Wong KHK, Khankhel AH, et al. Microfluidic isolation of platelet‐covered circulating tumor cells. Lab Chip. 2017;17(20):3498‐3503. Heeke S, Mograbi B, Alix‐Panabières C, Hofman P. Never travel alone: the crosstalk of circulating tumor cells and the blood microenvironment. Cells. 2019;8(7):714. Eslami‐S Z, Cortés‐Hernández LE, Thomas F, Pantel K, Alix‐Panabières C. Functional analysis of circulating tumour cells: the KEY to understand the biology of the metastatic cascade. Br J Cancer. 2022;127(5):800‐810. Winograd P, Hou S, Court CM, et al. Hepatocellular carcinoma–circulating tumor cells expressing PD‐L1 are prognostic and potentially associated with response to checkpoint inhibitors. Hepatol Commun. 2020;4(10):1527‐1540. Bidard FC, Jacot W, Kiavue N, et al. Efficacy of circulating tumor cell count‐driven vs clinician‐driven first‐line therapy choice in hormone receptor‐positive, ERBB2‐negative metastatic breast cancer: the STIC CTC randomized clinical trial. JAMA Oncol. 2021;7(1):34‐41. Müller V, Banys‐Paluchowski M, Friedl TWP, et al. Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program. ESMO Open. 2021;6(6):100299. Zhu C, Wei Y, Wei X. AXL receptor tyrosine kinase as a promising anti‐cancer approach: functions, molecular mechanisms and clinical applications. Mol Cancer. 2019;18(1):153. Brown M, Black JRM, Sharma R, Stebbing J, Pinato DJ. Gene of the month: Axl. J Clin Pathol. 2016;69(5):391‐397. Meyer AS, Miller MA, Gertler FB, Lauffenburger DA. The receptor AXL diversifies EGFR signaling and limits the response to EGFR‐targeted inhibitors in triple‐negative breast cancer cells. Sci Signal. 2013;6(287):ra66. Huang J‐S, Cho CY, Hong CC, et al. Oxidative stress enhances Axl‐mediated cell migration through an Akt1/Rac1‐dependent mechanism. Free Radic Biol Med. 2013;65:1246‐1256. Auyez A, Sayan AE, Kriajevska M, Tulchinsky E. AXL receptor in cancer metastasis and drug resistance: when normal functions go askew. Cancers (Basel). 2021;13(19):4864. Goyette MA, Duhamel S, Aubert L, et al. The receptor tyrosine kinase AXL is required at multiple steps of the metastatic cascade during HER2‐positive breast cancer progression. Cell Rep. 2018;23(5):1476‐1490. Antony J, Huang RY. AXL‐driven EMT state as a targetable conduit in cancer. Cancer Res. 2017;77(14):3725‐3732. Wang C, Jin H, Wang N, et al. Gas6/Axl axis contributes to chemoresistance and metastasis in breast cancer through Akt/GSK‐3beta/beta‐catenin signaling. Theranostics. 2016;6(8):1205‐1219. Gjerdrum C, Tiron C, Høiby T, et al. Axl is an essential epithelial‐to‐mesenchymal transition‐induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci U S A. 2010;107(3):1124‐1129. Koorstra JB, Karikari CA, Feldmann G, et al. The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther. 2009;8(7):618‐626. Tanaka M, Siemann DW. Gas6/Axl signaling pathway in the tumor immune microenvironment. Cancer (Basel). 2020;12(7):1850. Goyette M‐A, Côté J‐F. AXL receptor tyrosine kinase as a promising therapeutic target directing multiple aspects of cancer progression and metastasis. Cancer (Basel). 2022;14(3):466. Guo Z, Li Y, Zhang D, Ma J. Axl inhibition induces the antitumor immune response which can be further potentiated by PD‐1 blockade in the mouse cancer models. Oncotarget. 2017;8(52):89761‐89774. Aguilera TA, Rafat M, Castellini L, et al. Reprogramming the immunological microenvironment through radiation and targeting Axl. Nat Commun. 2016;7(1):13898. Kasikara C, Davra V, Calianese D, et al. Pan‐TAM tyrosine kinase inhibitor BMS‐777607 enhances anti–PD‐1 mAb efficacy in a murine model of triple‐negative breast cancer. Cancer Res. 2019;79(10):2669‐2683. Li Z, Chen L, Qin Z. Paradoxical roles of IL‐4 in tumor immunity. Cell Mol Immunol. 2009;6(6):415‐422. Zhang S, Xu XS, Yang JX, Guo JH, Chao TF, Tong YX. The prognostic role of Gas6/Axl axis in solid malignancies: a meta‐analysis and literature review. Onco Targets Ther. 2018;11:509‐519. Li Y, Ye X, Tan C, et al. Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene. 2009;28(39):3442‐3455. Saunus JM, Smart CE, Kutasovic JR, et al. Multidimensional phenotyping of breast cancer cell lines to guide preclinical research. Breast Cancer Res Treat. 2018;167(1):289‐301. D'Alfonso TM, Hannah J, Chen Z, Liu Y, Zhou P, Shin SJ. Axl receptor tyrosine kinase expression in breast cancer. J Clin Pathol. 2014;67(8):690‐696. Chen L, Gibbons DL, Goswami S, et al. Metastasis is regulated via microRNA‐200/ZEB1 axis control of tumour cell PD‐L1 expression and intratumoral immunosuppression. Nat Commun. 2014;5(1):5241. de Bono JS, Scher HI, Montgomery RB, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration‐resistant prostate cancer. Clin Cancer Res. 2008;14(19):6302‐6309. Cohen SJ, Punt CJ, Iannotti N, et al. Relationship of circulating tumor cells to tumor response, progression‐free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26(19):3213‐3221. Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each follow‐up time point during therapy of metastatic breast cancer patients predict progression‐free and overall survival. Clin Cancer Res. 2006;12(14):4218‐4224. Tanaka K, Tokunaga E, Inoue Y, et al. Impact of expression of vimentin and Axl in breast cancer. Clin Breast Cancer. 2016;16(6):520‐526.e2. Jin G, Wang Z, Wang J, et al. Expression of Axl and its prognostic significance in human breast cancer. Oncol Lett. 2017;13(2):621‐628. Ikeda M, Koh Y, Teraoka S, et al. Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system. Cancer Med. 2020;9(6):2122‐2133. Bidard FC, Proudhon C, Pierga JY. Circulating tumor cells in breast cancer. Mol Oncol. 2016;10(3):418‐430. Eslami SZ, Cortés‐Hernández LE, Glogovitis I, et al. In vitro cross‐talk between metastasis‐competent circulating tumor cells and platelets in colon cancer: a malicious association during the harsh journey in the blood. Front Cell Dev Biol. 2023;11:1209846. Leconet W, Chentouf M, du Manoir S, et al. Therapeutic activity of anti‐AXL antibody against triple‐negative breast cancer patient‐derived xenografts and metastasis. Clin Cancer Res. 2017;23(11):2806‐2816. Adam‐Artigues A, Arenas EJ, Martínez‐Sabadell A, et al. Targeting HER2‐AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer. Sci Adv. 2022;8(20):eabk2746. Lin J‐Z, Wang ZJ, de W, et al. Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer. Oncotarget. 2017;8(25):41064‐41077. |
| معلومات مُعتمدة: | MUSE grant "KIM Biomarkers and therapy", University of Montpellier |
| فهرسة مساهمة: | Keywords: AXL; circulating biomarker; circulating tumor cells; liquid biopsy; metastatic breast cancer |
| المشرفين على المادة: | 0 (Axl Receptor Tyrosine Kinase) EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases) 0 (Proto-Oncogene Proteins) 0 (AXL protein, human) 0 (Biomarkers, Tumor) |
| تواريخ الأحداث: | Date Created: 20231222 Date Completed: 20240805 Latest Revision: 20240805 |
| رمز التحديث: | 20240806 |
| مُعرف محوري في PubMed: | PMC10807582 |
| DOI: | 10.1002/cam4.6843 |
| PMID: | 38132919 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2045-7634 |
|---|---|
| DOI: | 10.1002/cam4.6843 |